Brief: Advicenne’S Flagship ADV7103 Receives Authorization For Pivotal Phase II/III Cystinuria Study In Belgium

Advicenne SA

07/01/2019 16:53

Jan 7 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE’S FLAGSHIP ADV7103 RECEIVES AUTHORIZATION FOR
PIVOTAL
PHASE II/III CYSTINURIA STUDY IN BELGIUM
    * AUTHORIZATION EXTENDS PATIENT RECRUITMENT BASE OF EUROPEAN
PHASE
II/III CORAL STUDY, PREVIOUSLY AUTHORIZED IN FRANCE
    * DEVELOPMENTS WILL BE FINANCED WITH FUNDS RAISED BY
ADVICENNE,
WHICH CLOSED 2018 WITH A CASH POSITION OF MORE THAN 26 MEUR

Source text for Eikon:  ID:nBwb2ZfQ7a 
Further company coverage:  ADVIC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))